Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Launched by BUZZARD PHARMACEUTICALS · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for patients with advanced colorectal cancer that has not responded well to standard therapies. Specifically, the study is testing a medication called isunakinra, which is a type of immunotherapy, when combined with another approved immunotherapy called pembrolizumab. The goal is to see if this combination can help patients whose tumors are microsatellite stable and have specific genetic mutations (like KRAS) that make them harder to treat. To join the study, participants must be adults who have already completed at least one previous treatment for their cancer and have measurable disease.

Eligible participants are typically between the ages of 65 and 74, and they must meet certain health criteria to ensure they can safely take part in the trial. This includes having normal organ function and being free of significant ongoing health issues. Patients can expect to receive the investigational treatment and be closely monitored throughout the study for any side effects or changes in their condition. It’s important to note that women who are pregnant or breastfeeding cannot participate, and there are specific guidelines regarding prior treatments and overall health to ensure the safety of all participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * 1. Subjects must have:
• • Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum
• • Tumor is determined to be RAS-mutated (KRAS, NRAS or HRAS) and microsatellite stable/proficient in mismatch repair, as assessed by immunohistochemistry (IHC) and/or polymerase chain reaction (PCR)/next generation sequencing (NGS) in a Clinical Laboratory Improvement Act (CLIA) environment and with a tumor mutational burden (TMB) of 10 MB or more.
• • 2. The study patients are required to have measurable disease by radiographic criteria (RECIST 1.1 and iRECIST).
• • 3. Prior therapy: Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease (with or without PD-1 inhibitors), with no available therapy likely to convey clinical benefit, or not be candidates for therapy of proven efficacy for their disease.
• • 4. There should be a minimum of 4 weeks from any prior chemotherapy (except for the nitrosoureas and mitomycin C, requiring a minimum of 6 weeks), immunotherapy and/or radiation. Patients with prostate cancer on hormone deprivation therapy may continue that therapy while on study.
• • 5. Patients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapy (for example, alopecia is not clinically significant).
• 6. ECOG performance status ≤ 1 7. Patients must have normal organ and hematologic function as defined below:
• • Serum creatinine ≤ 1.5 x upper limit of normal OR creatinine clearance and a 24-h urine collection of ≥ 60 mL/min.
• • ALT and AST ≤ 3x the upper limits of normal.
• • Total bilirubin ≤ 1.5 x upper limit of normal OR in patients with Gilbert's syndrome, a total bilirubin ≤ 3.0.
• * Hematological eligibility parameters (within 16 days of starting therapy):
• • Granulocyte count ≥ 1,500/mm3
• • Platelet count ≥ 75.000/mm3 8. Patients must have baseline pulse oximetry \> 90% on room air at rest.
• Exclusion Criteria:
• 1. Subjects must have:
• • ⦁ Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum
• • • Tumor is determined to be RAS-mutated (KRAS, NRAS or HRAS) and microsatellite stable/proficient in mismatch repair, as assessed by immunohistochemistry (IHC) and/or polymerase chain reaction (PCR)/next generation sequencing (NGS) in a Clinical Laboratory Improvement Act (CLIA) environment and with a tumor mutational burden (TMB) of 10 MB or more.
• • 2. The study patients are required to have measurable disease by radiographic criteria (RECIST 1.1 and iRECIST).
• • 3. Prior therapy: Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease (with or without PD-1 inhibitors), with no available therapy likely to convey clinical benefit, or not be candidates for therapy of proven efficacy for their disease.
• • 4. There should be a minimum of 2 weeks wash out period from chemotherapy and/or radiation therapy, and 4 weeks wash out period for immunotherapy.
• • 5. Patients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapy (for example, alopecia is not clinically significant).
• • 6. ECOG performance status ≤ 1
• 7. Patients must have normal organ and hematologic function as defined below:
• • Serum creatinine ≤ 1.5 x upper limit of normal OR creatinine clearance and a 24-h urine collection of ≥ 60 mL/min.
• • ALT and AST ≤ 3x the upper limits of normal.
• • Total bilirubin ≤ 1.5 x upper limit of normal OR in patients with Gilbert's syndrome, a total bilirubin ≤ 3.0.
• * Hematological eligibility parameters (within 16 days of starting therapy):
• • Granulocyte count ≥ 1,500/mm3
• • Platelet count ≥ 75.000/mm3
• • 8. Patients must have baseline pulse oximetry \> 90% on room air at rest.
• • Exclusion criteria
• • 1. Pregnant women or women presently breast-feeding their children are excluded due to unknown risks to a developing fetus or infant, confirmed by negative pre-treatment serum pregnancy test.
• • 2. Concurrent treatment for cancer, with specific exceptions noted in inclusion criteria.
• • 3. Any significant disease that, in the opinion of the investigator, may impair the patient's tolerance of study treatment.
• • 4. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
• • 5. Active autoimmune diseases requiring treatment. However, patients with vitiligo, alopecia, or clinically stable autoimmune endocrine disease who are on stable dosing of appropriate replacement therapy (if such therapy is indicated) are eligible.
• • 6. Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use. Limited pharmacologic doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent iv contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed.
• • 7. Patients who are receiving any other investigational agents within 28 days before start of study treatment.
• • 8. Patients with untreated central nervous system metastases or local treatment of brain metastases within the last 2 months. Patients with stable brain metastasis for 2 months post-intervention are eligible.
• • 9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab or any of its excipients or a history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in study.
• • 10. Serious or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
• • 11. HIV-positive patients are ineligible because of the potential for decreased immune response.
• • 12. Patients unwilling to use adequate contraception (defined as hormonal or barrier method or abstinence) prior to study entry are excluded. If the patient needs to be on adequate contraception, contraception must start before study entry and continue for 3 months after completion of study therapy.